MET and neoplasm: Capmatinib exerts its activity by inhibiting the MET phosphorylation triggered by the binding of HGF or by METamp, as well as MET-mediated phosphorylation of the different downstream signaling proteins, which results in the impaired proliferation and survival of the MET-dependent tumor cells [9].